StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

(o-(-2,6-Dichloranilino)phenyl)-essigsäure, Natrium-Salz

Diclofenac sodium

HCID 5018304
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
15307-79-6
Standard-SMILES
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]
InChIKey
KPHWPUGNDIVLNH-UHFFFAOYSA-M
Summenformel
C14H10Cl2NNaO2
Durchschnittliche Molmasse
318,1 g/mol
Monoisotopische Masse
316,9986282

Überblick

Diclofenac sodium is the sodium salt of diclofenac. It contains a diclofenac(1-).

Namen und Bezeichner

Bevorzugter Name
Diclofenac sodium
IUPAC
sodium 2-[2-(2,6-dichloroanilino)phenyl]acetate
Lokaler Name
(o-(-2,6-Dichloranilino)phenyl)-essigsäure, Natrium-Salz
Englischer Name
Diclofenac sodium
Summenformel
C14H10Cl2NNaO2
Molmasse
318.13

Namen und Synonyme

Diclofenac sodium15307-79-6Diclofenac sodium saltSodium diclofenacSolarazeNeriodinProphenatinVoltarenDiclophenac sodiumAbitrenBenfofenDyloject
Weitere Namen anzeigen
tsudohminDiclofenac SodiuAceclofenac EP IMpurity ASODIUM 2-(2,6-DICHLOROANILINO)PHENYLACETATEsodium 2-[2-(2,6-dichloroanilino)phenyl]acetateN-(2,6-Dichlorophenyl)-o-aminophenylacetic acid sodium saltNaclof
EcofenacPennsaidVoltareneVoltaren-XRGP 45840DiclophlogontDealgicDeflamat

Datenbank-Bezeichner

CAS
15307-79-6
PubChem CID
5018304
DTXSID
DTXSID3037208
ChEMBL
CHEMBL1034
ChEBI

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
52,2 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
4
Schwere Atome
20
Formalladung
0
Komplexität
310

Experimentelle und physikochemische Eigenschaften

Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal DrugsActive Ingredients (Diclofenac sodium) -> FDA Greenbook
Collision Cross Section157.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
288 · 288-290°C
Dichte
0.781 g/cm3 · 0.781 g/cm3
storage temp.
room temp
Löslichkeit
2 O: · H2O: 50 mg/mL
pka
4 · 4(at 25℃)
Aggregatzustand
White solid
Farbe
White to Almost white
Biologische Quelle
synthetic

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (96.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P316, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 243 reports by companies from 43 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

Status: Active Update: 27-05-2019 https://echa.europa.eu/registration-dossier/-/registered-dossier/13423

Diclofenac sodium: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (96.7%)

Toxikologische Informationen

Exposure RoutesCompletely absorbed from the gastrointestinal tract.
Toxicity Summary · 1 Eintrag

The antiinflammatory effects of diclofenac are believed to be due to inhibition of both leukocyte migration and the enzyme cylooxygenase (COX-1 and COX-2), leading to the peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis is responsible for the analgesic effects of diclofenac. Antipyretic effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat dissipation.

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Hepatic. Route of Elimination: Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites. Half Life: 2 hours

FDA Pharmacological Classification · 6 Einträge

DICLOFENAC SODIUM

Cyclooxygenase Inhibitors [MoA]; Nonsteroidal Anti-inflammatory Drug [EPC]; Anti-Inflammatory Agents, Non-Steroidal [CS]; Decreased Prostaglandin Production [PE]

DICLOFENAC SODIUM 1%

Cyclooxygenase Inhibitors [MoA]; Anti-Inflammatory Agents, Non-Steroidal [CS]; Decreased Prostaglandin Production [PE]; Nonsteroidal Anti-inflammatory Drug [EPC]

DICLOFENAC SODIUM D/R

Cyclooxygenase Inhibitors [MoA]; Nonsteroidal Anti-inflammatory Drug [EPC]; Decreased Prostaglandin Production [PE]; Anti-Inflammatory Agents, Non-Steroidal [CS]

MeSH Pharmacological Classification · 2 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Verwendung und Herstellung

UsesFor the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.

Zugehörige Reaktionen

24
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 356790
HRID 356790als Edukt
Reaktionsgleichung von HRID 371113
HRID 371113als Edukt
Reaktionsgleichung von HRID 464711
HRID 464711als Edukt
Reaktionsgleichung von HRID 990889
HRID 990889als Edukt
Reaktionsgleichung von HRID 1360001
HRID 1360001als Edukt
Reaktionsgleichung von HRID 1420867
HRID 1420867als Edukt
Reaktionsgleichung von HRID 1517222
HRID 1517222als Edukt
Reaktionsgleichung von HRID 1660668
HRID 1660668als Edukt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
CHEBI:4509
UNII
QTG126297Q
EC Number
239-346-4
Nikkaji
J8.556A
Wasserlöslichkeit
50 mg/ml · Soluble in water to 50mg/ml.
Merck
14 · 14,3081
BCS Class
2 · 2
Stabilität
Stable.
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
InChI=1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1
InChIKey
KPHWPUGNDIVLNH-UHFFFAOYSA-M
SMILES
C1(=CC=CC=C1CC([O-])=O)NC1=C(Cl)C=CC=C1Cl.[Na+]
CAS Datenbank
15307 · 15307-79-6(CAS DataBase Reference)
Signs and SymptomsSymptoms of overdose include loss of consciousness, increased intracranial pressure, and aspiration pneumonitis.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Diclofenac sodium

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub>=390mg/kg (orally in mice)

Sicherheitsdaten

wgk
3
ridadr
UN 2811 6.1/PG 3
hs_code
29224999
RTECS-Nr.
AG6330000
risk_code
25-36/37/38-63
Toxizität
LD50 in mice, rats (mg/kg): ~390, 150 orally (Krupp)
hazard_code
T,Xi
safety_code
22-36/37-45-36-26-60-20
hazard_class
6.1(b)
packing_group
III
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 3 OralAquatic Chronic 2Repr. 2STOT RE 1
Use ClassificationAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
Anwendungen · 3 Einträge

BeschreibungDiclofenac is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 0.9-2.7 and 1.5-20 μM, for human COX-1 and COX-2, respectively). It is also an active metabolite of diclofenac methyl ester and diclofenac amide . Diclofenac inhibits release of arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) induced by A23187 in isolated rat peritoneal neutrophils and macrophages (IC50s = 60 and 10 μM, respectively). Transdermal administration of diclofenac inhibits carrageenan-induced paw edema in rats. Formulations containing diclofenac have been used in the treatment of pain associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

HistoryDiclofenac sodium is a classic nonsteroidal anti-inflammatory drug (NSAID), known for its potent antipyretic, analgesic, and anti-inflammatory effects, and is marketed under brand names such as Voltaren. Its discovery and widespread use have had a profound impact on the treatment of pain and inflammation.Discovery and Patent (1965): Diclofenac sodium was synthesized by a team of researchers Rudolf Pfister and Alfred Sallmann at the Swiss pharmaceutical company Ciba-Geigy AG (now part of Novartis) while searching for a highly active and well-tolerated NSAID. The compound was patented in 1965.First Market Launch (1973): After extensive preclinical and clinical trials, diclofenac sodium was first marketed globally in 1973 under the brand name Voltaren. Its design philosophy is based on clear principles and aims to be an effective cyclooxygenase (COX) inhibitor.

VerwendenDiclofenac sodium is a nonsteroidal anti-inflammatory compound and cyclooxygenase (COX) inhibitor. Oxidation of diclofenac sodium produces the metabolite 4'-hydroxy diclofenac) which demonstrates specific inhibition of Cox-2. Inhibition of Cox by diclofenac and 4'-hydroxy diclofenac suppresses prostaglandin E2 synthesis, producing anti-inflammatory and analgesic effects. Diclofenac is also shown to stabilize the native tetrameric conformation of transthyretin (TTR) fibrils, preventing the formation of insoluble amyloidogenic TTR deposits. Diclofenac Sodium is a substrate of CYP2C9. It is also used as an inhibitor of Cox-1 and Cox-2.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

EthanolChloracetylchlorid2,6-Dichlorphenol2-ChlorbenzoesäureAnilin2,5-DichloranilinChlortoluol (o)2,6-DichloranilinNatriumhydroxidAluminiumchlorid

Nachgelagerte Produkte

1-(2,6-Dichlorphenyl)-1,3-dihydro-2H-indol-2-onDiclofenac methyl ester2,3-Dihydroindol-2-on

Ergänzende Hinweise

DefinitionChEBI: Diclofenac sodium is the sodium salt of diclofenac. It contains a diclofenac(1-).